Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 56.3% Potential Upside Indicated by Cantor Fitzgerald
broker ratings

Hikma Pharmaceuticals Plc 56.3% Potential Upside Indicated by Cantor Fitzgerald

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Cantor Fitzgerald. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Cantor Fitzgerald have set their target price at 2500 GBX on its stock. This would imply the analyst believes there is now a potential upside of 56.3% from today’s opening price of 1600 GBX. Over the last 30 and 90 trading days the company share price has decreased 271 points and decreased 438 points respectively. The 52 week high share price is 2703 GBX while the 52 week low for the share price is 1573 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,983.54 GBX and a 200 day moving average of 1,972.86. There are currently 240,880,235 shares in issue with the average daily volume traded being 747,675. Market capitalisation for LON:HIK is £3,916,712,621 GBP.

You might also find these articles of interest:

Register here to be notified of future articles like this
Get all our broker ratings on Twitter as they are published!